SCHEMBL5877311

SCHEMBL5877311

Cc1ccc(S(=O)(=O)n2nc(Nc3ccccc3)c3c2CC(c2cccc(N(C)C)c2)(c2cccc(N(C)C)c2)C=C3)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.34
ALDH1A1 P00352 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PIM1 P11309 1/20 0.33
MEN1 O00255 3/20 0.33
GAA P10253 3/20 0.33
KMT2A Q03164 3/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NR1H2 P55055 1/20 0.32
NR1H3 Q13133 1/20 0.32
NPY5R Q15761 1/20 0.32
CYP2C19 P33261 1/20 0.31
CA12 O43570 1/20 0.30
CA9 Q16790 1/20 0.30
HCRTR1 O43613 1/20 0.30
HCRTR2 O43614 1/20 0.30
CNR2 P34972 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876345 0.99 MAPT (0.33) MAPTALDH1A1SMN1; SMN2PIM1MEN1
SCHEMBL5875901 0.92 MAPT (0.39) MAPTALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL5878272 0.91 MAPT (0.39) MAPTALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL5875996 0.90 NR1H2 (0.38) MAPTALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL5877371 0.88 KMT2A (0.36) MAPTALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL5876609 0.88 ALDH1A1 (0.34) MAPTALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL5875964 0.87 KMT2A (0.35) MAPTALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL5876542 0.87 MAPT (0.33) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5875884 0.87 STAT1 (0.41) MAPTALDH1A1MEN1GAAKMT2A
SCHEMBL5877528 0.86 MAPT (0.33) MAPTALDH1A1SMN1; SMN2MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT MAPT 1879/4885ALDH1A1 166/4885SMN1; SMN2 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.